Surgical outcomes and rate of pathological response in resectable/borderline resectable pancreatic cancer patients undergoing neoadjuvant gemcitabine/nab-paclitaxel versus FOLFIRINOX: A retrospective institutional analysis.

Abraham Attah Attah,Saleha Rizwan,Khaled Alhamad,Micheal Turk,Palash Asawa,Karthik Shankar,Lynna Alnimer,Srividya Srinivasamaharaj,Yazan Samhouri,Dulabh K. Monga

Surgical outcomes and rate of pathological response in resectable/borderline resectable pancreatic cancer patients undergoing neoadjuvant gemcitabine/nab-paclitaxel versus FOLFIRINOX: A retrospective institutional analysis.

2021

Abraham Attah Attah
Saleha Rizwan
Khaled Alhamad
Micheal Turk
Palash Asawa
Karthik Shankar
Lynna Alnimer
Srividya Srinivasamaharaj
Yazan Samhouri
Dulabh K. Monga

e16247Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors, predicted to become the second leading cause of cancer related death in some regions of the wo...

Keywords:

Internal medicine
Gemcitabine
Medicine
borderline resectable
Pancreatic cancer
Oncology
Nab-paclitaxel
Cancer
pancreatic ductal adenocarcinoma
FOLFIRINOX
pathological response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations